With $445 million deal, Peninsula company restocks for another run with a late-stage drug


The company also raised $210 million from a group of existing investors.

Previous Stock Yards Bank continues to grow its reach in Greater Cincinnati
Next Kidney care provider DaVita adds to board of directors